Announcements Trials
Browse Landscape

Phase

Phase 3 6Phase 2 1

Status

Completed 7

Sponsor Class

INDUSTRY 7OTHER 2

Study Type

Interventional 7

Sponsor

Cancer Type

Gynecologic 4

Conditions

Condylomata Acuminata 4Uterine Cervical Neoplasms 3Papillomavirus Infections 3Vulvar Neoplasms 1Vaginal Neoplasms 1Uterine Cervical Dysplasia 1

Interventions

Paclitaxel 337pembrolizumab 332Carboplatin 330Cisplatin 277Gemcitabine 264Docetaxel 251Bevacizumab 239Nivolumab 230Pemetrexed 211Rituximab 183Dexamethasone 183Cyclophosphamide 169Capecitabine 169Trastuzumab 149Fluorouracil 147Ipilimumab 121atezolizumab 118Prednisone 117Erlotinib Hydrochloride 116Oxaliplatin 109Cetuximab 104Sunitinib 101Leucovorin 97Doxorubicin 97Lenalidomide 93Irinotecan 89130-nm albumin-bound paclitaxel 84durvalumab 77Bortezomib 77Azacitidine 73

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

7 trials
RecentStart dateEnrollment
INDUSTRY × Has results × Vaccines, Synthetic × Clear all
NCT00092534 2025-08-01

FUTURE II

Merck Sharp & Dohme LLC

Phase 3 Completed
12,167 enrolled 23 charts
Gynecologic

Uterine Cervical Neoplasms, Condylomata Acuminata

NCT03493542 2024-12-31

V501-213

Merck Sharp & Dohme LLC

Phase 3 Completed
766 enrolled 38 charts
Gynecologic

Uterine Cervical Dysplasia

NCT01245764 2018-11-14

GARDASILâ„¢ Study in Healthy Females Between 9 and 26 Years of Age in Sub-Saharan Africa (V501-046)

Merck Sharp & Dohme LLC

Phase 3 Completed
250 enrolled 20 charts
Gynecologic

Uterine Cervical Neoplasms, Condylomata Acuminata, Vaginal Neoplasms, Vulvar Neoplasms, Papillomavirus Infections

NCT00090285 2018-08-23

V501-020

Merck Sharp & Dohme LLC

Phase 3 Completed
4,065 enrolled 27 charts

Condylomata Acuminata

NCT00411749 2017-04-21

V501 Immunogenicity Study in Females Age 9 to 17 Years (V501-028)

Merck Sharp & Dohme LLC

Phase 2 Completed
107 enrolled 12 charts

Papillomavirus Infections

NCT00496626 2017-04-17

An Immunogenicity and Safety Study of Gardasil® in Chinese Subjects (V501-030)(COMPLETED)

Merck Sharp & Dohme LLC

Phase 3 Completed
600 enrolled 12 charts

Papillomavirus Infections

NCT00092495 2015-01-13

Study of an Investigational Vaccine in Pre-Adolescents and Adolescents (Gardasil)(V501-016)

Merck Sharp & Dohme LLC

Phase 3 Completed
3,055 enrolled 25 charts
Gynecologic

Uterine Cervical Neoplasms, Condylomata Acuminata

Data powered by HemOnc (CC BY 4.0) Colophon âš¡